Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) EBT (2023 - 2025)

CG Oncology's EBT history spans 3 years, with the latest figure at -$41.3 million for Q4 2025.

  • For Q4 2025, EBT fell 29.72% year-over-year to -$41.3 million; the TTM value through Dec 2025 reached -$160.8 million, down 82.69%, while the annual FY2025 figure was -$160.8 million, 82.69% down from the prior year.
  • EBT reached -$41.3 million in Q4 2025 per CGON's latest filing, up from -$43.7 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$8.7 million in Q1 2023 to a low of -$43.7 million in Q3 2025.
  • Average EBT over 3 years is -$24.8 million, with a median of -$19.7 million recorded in 2024.
  • The largest YoY upside for EBT was 29.72% in 2025 against a maximum downside of 119.05% in 2025.
  • A 3-year view of EBT shows it stood at -$16.6 million in 2023, then crashed by 92.16% to -$31.8 million in 2024, then decreased by 29.72% to -$41.3 million in 2025.
  • Per Business Quant, the three most recent readings for CGON's EBT are -$41.3 million (Q4 2025), -$43.7 million (Q3 2025), and -$41.4 million (Q2 2025).